---
title: "CervoMed Soars 74% During Trading After US Patent Extension to 2042"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290212936.md"
description: "CervoMed jumped 74% after USPTO granted patent extension for neflamapimod treating DLB through 2042."
datetime: "2026-06-18T14:14:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290212936.md)
  - [en](https://longbridge.com/en/news/290212936.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290212936.md)
---

# CervoMed Soars 74% During Trading After US Patent Extension to 2042

CervoMed(CRVO.US) 盘中**涨 74.57%**，现报**6.651 美元**。公司获得美国专利商标局关于 neflamapimod 用于治疗纯路易体痴呆症的专利许可，保护期延长至 2042 年。该专利针对无显著阿尔茨海默病样 tau 病理的 DLB 患者。Neflamapimod 已完成 2b 期临床试验，3 期试验时间取决于获得合作伙伴关系或额外融资。

### Related Stocks

- [CRVO.US](https://longbridge.com/en/quote/CRVO.US.md)

## Related News & Research

- [Cervo posts investor presentation on website covering clinical, development and financial updates](https://longbridge.com/en/news/289829022.md)
- [CervoMed Posts Updated Investor Presentation and Business Overview](https://longbridge.com/en/news/289834335.md)
- [CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules | CRVO Stock News](https://longbridge.com/en/news/290228255.md)
- [Roth MKM Reaffirms Their Buy Rating on CervoMed (CRVO)](https://longbridge.com/en/news/289519604.md)
- [CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | CRVO Stock News](https://longbridge.com/en/news/289591456.md)